All 1 tracked stories fall under one category: market-trends. Mark Newcomer is most often covered alongside Dyadic International, which appears in 1 of these 1 story. We currently track 1 Healthcare story that mention Mark Newcomer, all published on March 26, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Mark Newcomer
All 1 tracked stories fall under one category: market-trends. Mark Newcomer is most often covered alongside Dyadic International, which appears in 1 of these 1 story. We currently track 1 Healthcare story that mention Mark Newcomer, all published on March 26, 2026. Each carries 5 original sources on average.
Stories tracked
1
Sources per story
5
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 8 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Mark Newcomer. Shared-story counts are live from our verified record — not editorial picks.
The Q4 2025 earnings cycle marks a critical transition for mid-cap biotech and health-IT firms as they shift from R&D-heavy profiles to commercial-stage entities. Key players like Dyadic and Precigen are reporting initial product revenues and expanded distribution networks, while service providers like Paysign see massive growth in patient affordability programs.
